

# Quantitative Ultrasound for Liver Steatosis Assessment: Benefits of Measurements Over a Large Two-dimensional Region of Interest on the Performance of Image-brightness-based Parameters

A. BESSON<sup>1</sup>, B. HERIARD-DUBREUIL<sup>1</sup>, V. DE LEDINGHEN<sup>2</sup>, D. COHEN-DUTARTRE<sup>3</sup>, F. MANON<sup>2</sup>, J. ABIVEN<sup>2</sup>, A.-L. DE ARAUJO<sup>2</sup>, R. HOUMADI<sup>4</sup>, J. DUPUY<sup>4</sup>, J. FOUCHER<sup>2</sup>, J. GAY<sup>1</sup>, C. COHEN-BACRIE<sup>1</sup>

<sup>1</sup>E-Scopics, Aix-en-Provence, France / <sup>2</sup>Hepatology outpatient clinic, Bordeaux University Hospital, Pessac, France / <sup>3</sup>Inria Bordeaux Sud-Ouest, Bordeaux, France / <sup>4</sup>Clinical Research Unit, Bordeaux University Hospital, Pessac, France

## 1 Introduction

- Ultrasound (US) is the **first line non-invasive** modality to screen for significant **steatosis** [1], using qualitative assessment of liver **US brightness**.
- US propagation properties of tissues **correlate with fat content** [2].
- We use **quantitative** brightness-derived parameters, **US attenuation** (UA) and **backscatter coefficient** (BSC).
- Fibroscan® Controlled Attenuation Parameter (CAP™) captures a **1D-single beam** US signal to estimate UA. Independent measurements are **accumulated over time**.

## 4 Results

		Small ROI	Medium ROI	Large ROI
Inter-operator Reproducibility	ICC <sub>UA</sub> [CI 95%]	0.72 [0.56-0.83]	0.81 [0.68-0.89]	0.92 [0.85-0.96]
	ICC <sub>BSC</sub> [CI 95%]	0.80 [0.69-0.88]	0.84 [0.73-0.91]	0.93 [0.88-0.97]
Intra-operator Reproducibility (experts)	ICC <sub>UA</sub> [CI 95%]	0.77 [0.61-0.87]	0.82 [0.69-0.90]	0.93 [0.86-0.97]
	ICC <sub>BSC</sub> [CI 95%]	0.83 [0.71-0.90]	0.89 [0.79-0.94]	0.94 [0.88-0.97]
Intra-operator Reproducibility (novices)	ICC <sub>UA</sub> [CI 95%]	0.79 [0.64-0.88]	0.89 [0.78-0.94]	0.91 [0.77-0.96]
	ICC <sub>BSC</sub> [CI 95%]	0.86 [0.76-0.93]	0.91 [0.83-0.96]	0.93 [0.84-0.97]
Correlation with new CAP ( $r^2$ )	$r^2_{UA}$	0.48	0.51	0.6
	$r^2_{BSC}$	0.57	0.59	0.64
Failure rate		8% (5 patients)	10% (6 patients)	22% (13 patients)
				

## 5 Conclusions

UA and BSC measurements can be performed with Hepatoscope™ with very good reproducibility and repeatability.

- The **larger the ROI**, the more robust the measurements.
- A **single value** over a large ROI is enough to estimate UA and BSC reliably, paving the way to **low exam times** for liver steatosis assessment.

Future comparative studies with MRI-PDFF and histological scores will allow better assessment of this method to estimate UA and BSC for steatosis staging.

## 2 Aim

1. Assess performances of brightness-derived parameters on ultraportable point-of-care device Hepatoscope™, using a **2D region of interest (ROI)**.
1. Assess the **impact of the ROI size** over the **robustness** of UA and BSC measurements.




Figure 1: Evolution of inter-operator reproducibilities of BSC and UA with the size of the ROI.

## 3 Method

- Single center study with 60 patients (NCT04782050).
- Fibroscan® CAP™ + 4 Hepatoscope liver-exams.
- 2 operators: 1 novice and 1 expert, blinded to values.
- 10 consecutive sets of US raw data were collected each time.
- UA and BSC computed on 3 different ROI sizes.
- Assessment of intra- and inter-operator reproducibility (ICC with 95% CI).
- Correlations vs. Fibroscan® CAP™.




Figure 2: Number of measurements needed to obtain very good inter-operator reproducibilities of BSC and UA.

**Brightness-Based Quantitative Ultrasound: The Larger The Region of Interest, The More Robust The Measurements**

## 7 Contact information

Adrien Besson, adrien.besson@e-scopics.com